CRISPR Therapeutics AG 8-K Report: Key Insights & Updates

Here are the key pieces of information extracted from the provided section of the financial report:

1. Entity Information:

• Company Name: CRISPR Therapeutics AG
• CIK Number: 0001674416
• SEC File Number: 001-37923
• Headquarters Address: Baarerstrasse 14, 6300 Zug, Switzerland
• Phone Number: +41 (0)41 561 32 77

2. Report Type:

• Filing Type: 8-K (Current Report)

3. Reporting Period:

• Start Date: February 11, 2025
• End Date: February 11, 2025

4. Stock Information:

• Common Shares: The nominal value of shares is CHF 0.03.
• Ticker Symbol: CRSP
• Exchange: NASDAQ

5. XBRL Information:

• This section uses XBRL (eXtensible Business Reporting Language) for structured financial reporting, which is common in SEC filings.

Insights:

• The report is a current report (8-K), suggesting it contains significant information that shareholders and potential investors should be aware of, typically related to major events affecting the company.
• The filing date indicates that the information is likely timely and relevant to stakeholders.
• The nominal value of shares and the listing on NASDAQ provide context on the company's financial structure and market presence.

Overall, this section demonstrates the company's regulatory compliance and its operational details relevant to investors and analysts.